Teva Pharmaceuticals, a global pharmaceutical company, signed a strategic partnership and licensing agreement on Tuesday with NeuroGen, a China-based biopharmaceutical company, to advance the commercialization of AJOVY in the Chinese mainland.

Under the agreement, NeuroGen will obtain exclusive rights to commercialize AJOVY in the Chinese mainland along with exclusive licenses to related product patents and trademarks.

It will also become the marketing authorization holder for the product in the mainland market, according to Teva.

AJOVY, also known as fremanezumab, is an injectable drug developed by Teva for the preventive treatment of migraine. It offers both monthly and quarterly dosing options, giving patients greater flexibility in long-term disease management.

The move comes as migraine continues to pose a major health burden in China. Data cited by the company showed that around 185 million people in the country are living with the condition, driving demand for preventive therapies and broader access to long-term treatment.

Sean Chen, chief executive officer of NeuroGen, said the partnership would help bring the treatment closer to clinical practice and patient needs in China.

"We will leverage our local expertise and network to bring AJOVY closer to patient needs in China," Chen said.

Theodor Wee, general manager of Teva Greater China, said the cooperation reflects Teva's long-term commitment to neuroscience.

"We look forward to working with specialized partners to bring more accessible preventive treatment options to migraine patients," Wee said.